Advanced Proteome Therapeutics
Boston
About Advanced Proteome Therapeutics
Cancer is a complex disease, and for therapies to be maximally effective, they must distinguish between normal and cancerous cells. Combination therapies have been employed to counter the multiple mechanisms that tumors use to evade the immune response and resist the efficacious effects of therapeutics. Despite continuing challenges, useful synergies have been obtained with a combination of individual drugs, and, as a result, a broad range of drug types are now being combined because of the promise and the compelling rationale behind combination therapy. Thus, effective treatment for cancer requires not only the discovery of individual drugs with antitumor activity, but also knowledge of the best way to combine these drugs.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $3.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Aug 2022)
- Ticker: cve:APC
- Website: advancedproteome.com
- Phone: (617)638-0340
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/advanced-proteome-therapeutics-2297705 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.